Agenda
Session 1: Opening Remarks and Keynote Presentations
8:00 AM – 8:15 AM NCI Efforts in Cancer Nanotechnology
Dr. Piotr Grodzinski, Chief, Nanodelivery Systems and Devices Branch, National Cancer Institute, USA
8:15 AM – 8:30 AM Frederick National Laboratory for Cancer Research
Dr. Dwight Nissley, Director, Cancer Research and Technology Program, Frederick National Laboratory for Cancer Research,
USA
8:30 AM – 8:50 AM Nanotechnology Characterization Lab (NCL): Celebrating People and Science
Dr. Marina Dobrovolskaia and Dr. Stephan Stern, Directors, Nanotechnology Characterization Lab, USA
8:50 AM – 9:30 AM Keynote Presentation: National Priorities for Nanotechnology
Dr. Branden Brough, Director, National Nanotechnology Coordination Office, USA
9:30 AM – 10:10 AM Keynote Presentation: The Interdisciplinary Nature of Nanomedicine: Have We Achieved It?
Dr. Mauro Ferrari, Professor, University of Washington, USA
10:10 AM – 10:50 AM Keynote Presentation: Nanotechnology for Medicine: Past, Present and Future
Dr. Pieter Cullis, Professor, The University of British Columbia, Canada
Break (10 min)
Session 2 AM: Presentations from NCL Collaborators
11:00 AM – 11:20 AM Nano Candesartan Improves Therapeutic Efficacy of Immune Checkpoint Inhibitors via Tumor Microenvironment
Normalization
Dr. Yechezkel (Chezy) Barenholz, Professor, Hebrew University of Jerusalem, Israel
11:20 AM – 11: 40 AM The Nanoprimer: A Significant Opportunity to Boost the Efficacy of Nanomedicine.
Dr. Matthieu Germain, Sr. Director, Head of Curadigm platform, Nanobiotix SA, France
11:40 AM – 12:00 PM NanoEngineering Gone Viral: Plant Viruses Against Cancer
Dr. Nicole Steinmetz, Professor, University of California San Diego, USA
Lunch (60 min)
Session 2 PM: Presentations from NCL Collaborators
1:00 PM – 1:20 PM From albumin-based nab technology for small molecules to peptide-based delivery for RNA therapeutics.
Dr. Neil Desai, Founder and former CEO, Aadi Bioscience and Founder/CEO, Aanastra Inc.
1:20 PM – 1:40 PM Targeted Hyperthermia: A Nanotechnology-Enabled Medical Device Treatment for Solid Tumors.
Dr. Len Pagliaro, CSO, Sona Nanotech, USA
1:40 PM – 2:00 PM Nano-better Paclitaxel for TNBC
Dr. Glen Kwon, Professor, University of Wisconsin, USA
Break (10 min)
Session 3: Presentations from NCL Scientists and FNL CSO
2:10 PM – 2:30 PM Physicochemical Characterization Highlights
Dr. Jeffrey Clogston, Head of Physicochemical Characterization Section, Nanotechnology Characterization Lab, USA
2:30 PM – 2:50 PM Pharmacology and Toxicology Highlights
Dr. Stephan Stern, Head of Pharmacology and Toxicology Section, Nanotechnology Characterization Lab, USA
2:50 PM – 3:10 PM Immunology Highlights
Dr. Marina Dobrovolskaia, Head of Immunology Section, Nanotechnology Characterization Lab, USA
3:10 PM – 3:20 PM Mechanisms of Collaboration with NCL
Dr. Rachael Crist, Head of Strategic Client Relations Section, Nanotechnology Characterization Lab, USA
3:20 PM – 3.30 PM Future Outlook: National Lab's Role in Science, Standardization, Translational and Basic Science
Dr. Leonard Freedman, CSO, Frederick National Laboratory for Cancer Research, USA
Posters, Vendor Show, and Reception
3:30 PM – 5:00 PM Poster Presentations and Vendor Show
5:00 PM – 6:00 PM Reception